Stock listing

Frankfurt:4YX Rhelion Life Sciences Corp. Aktie

German listing (Frankfurt) of Rhelion Life Sciences Corp. · home listing CSE:RHEL

Follow Rhelion Life Sciences Corp. into a list and get an email when it puts out news.

Home listing price · CSE:RHEL

$0.02 CAD 0.00 (0.0%)

Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, CSE:RHEL · Data provided by Twelve Data

Past 3 months -20.0% · daily closes, Aug 4, 2026 – Oct 30, 2026, adjusted for splits

Day range: $0.02 – $0.02 CADOct 30, 2026
Volume: 4.24M sharesOct 30, 2026
Market cap: $12.28M CADAt the close on Oct 30, 2026 · price × 614.1M shares outstanding
Traded on an average day: $6,561 CADMedian day 110,733 shares · 2 days with no trades · last 3 months, Aug 4, 2026 – Oct 30, 2026

Prices by listing

Listing	Last	Change	Volume	Open	High	Low	Previous close	Price from
CSE:RHEL · Home	$0.02 CAD	0.00 (0.0%)	4,244,558	$0.02	$0.02	$0.02	$0.02	Close on Oct 30, 2026
OTC:TRUFF	$0.018 USD	+0.000 (+0.6%)	128,550	$0.018	$0.018	$0.018	$0.017	Close on Oct 27, 2026

Data provided by Twelve Data

Daily closes

Last 3 months, Aug 4, 2026 – Oct 30, 2026 · CSE:RHEL · CAD, adjusted for splits

Day	Close	Change	%	Open	High	Low	Volume
Fri, Oct 30	$0.02	0.00	0.0%	$0.02	$0.02	$0.02	4,244,558
Thu, Oct 29	$0.02	-0.005	-20.0%	$0.025	$0.025	$0.02	166,342
Wed, Oct 28	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	1,055
Tue, Oct 27	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	232,000
Mon, Oct 26	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	0
Fri, Oct 23	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	7,049
Thu, Oct 22	$0.025	0.00	0.0%	$0.025	$0.025	$0.02	38,000
Wed, Oct 21	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	64,751
Tue, Oct 20	$0.025	0.00	0.0%	$0.025	$0.025	$0.02	17,600
Mon, Oct 19	$0.025	0.00	0.0%	$0.02	$0.025	$0.02	63,000
Fri, Oct 16	$0.025	0.00	0.0%	$0.025	$0.025	$0.02	171,070
Thu, Oct 15	$0.025	0.00	0.0%	$0.03	$0.03	$0.025	106,660
Wed, Oct 14	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	111,544
Tue, Oct 13	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	54,553
Fri, Oct 9	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	507,150
Thu, Oct 8	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	104,000
Wed, Oct 7	$0.025	0.00	0.0%	$0.03	$0.03	$0.025	11,000
Tue, Oct 6	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	136,000
Mon, Oct 5	$0.025	0.00	0.0%	$0.025	$0.025	$0.025	65,300
Fri, Oct 2	$0.025	-0.005	-16.7%	$0.03	$0.03	$0.025	1,483,733
Thu, Oct 1	$0.03	0.00	0.0%	$0.03	$0.03	$0.03	151,000
Wed, Sep 30	$0.03	0.00	0.0%	$0.025	$0.03	$0.025	69,256
Tue, Sep 29	$0.03	0.00	0.0%	$0.03	$0.03	$0.03	22,000
Mon, Sep 28	$0.03	-0.005	-14.3%	$0.03	$0.03	$0.03	384,892
Fri, Sep 25	$0.035	+0.005	+16.7%	$0.03	$0.035	$0.03	419,257
Thu, Sep 24	$0.03	-0.005	-14.3%	$0.035	$0.035	$0.03	65,570
Wed, Sep 23	$0.035	0.00	0.0%	$0.03	$0.035	$0.03	62,029
Tue, Sep 22	$0.035	+0.003	+7.7%	$0.035	$0.035	$0.03	388,200
Mon, Sep 21	$0.032	+0.003	+8.3%	$0.03	$0.035	$0.03	127,130
Fri, Sep 18	$0.03	-0.003	-7.7%	$0.03	$0.03	$0.03	209,750
Thu, Sep 17	$0.032	+0.003	+8.3%	$0.035	$0.035	$0.03	130,014
Wed, Sep 16	$0.03	0.00	0.0%	$0.035	$0.035	$0.03	132,900
Tue, Sep 15	$0.03	-0.003	-7.7%	$0.03	$0.03	$0.03	160,301
Mon, Sep 14	$0.032	0.00	0.0%	$0.032	$0.032	$0.032	0
Fri, Sep 11	$0.032	+0.003	+8.3%	$0.032	$0.032	$0.03	218,000
Thu, Sep 10	$0.03	-0.005	-14.3%	$0.03	$0.032	$0.03	241,690
Wed, Sep 9	$0.035	+0.005	+16.7%	$0.03	$0.035	$0.03	502,650
Tue, Sep 8	$0.03	0.00	0.0%	$0.03	$0.03	$0.03	542,701
Fri, Sep 4	$0.03	0.00	0.0%	$0.025	$0.03	$0.025	20,830
Thu, Sep 3	$0.03	0.00	0.0%	$0.03	$0.03	$0.03	133,942
Wed, Sep 2	$0.03	0.00	0.0%	$0.035	$0.035	$0.03	107,000
Tue, Sep 1	$0.03	0.00	0.0%	$0.035	$0.035	$0.03	697,766
Mon, Aug 31	$0.03	+0.005	+20.0%	$0.025	$0.03	$0.025	658,077
Fri, Aug 28	$0.025	-0.005	-16.7%	$0.03	$0.035	$0.025	78,048
Thu, Aug 27	$0.03	+0.005	+20.0%	$0.03	$0.03	$0.025	346,050
Wed, Aug 26	$0.025	-0.005	-16.7%	$0.025	$0.025	$0.025	35,365
Tue, Aug 25	$0.03	0.00	0.0%	$0.03	$0.03	$0.03	25,357
Mon, Aug 24	$0.03	0.00	0.0%	$0.03	$0.03	$0.025	118,501
Fri, Aug 21	$0.03	+0.005	+20.0%	$0.025	$0.03	$0.025	84,100
Thu, Aug 20	$0.025	0.00	0.0%	$0.025	$0.03	$0.025	109,922
Wed, Aug 19	$0.025	0.00	0.0%	$0.03	$0.03	$0.025	81,000
Tue, Aug 18	$0.025	-0.005	-16.7%	$0.025	$0.025	$0.025	32,320
Mon, Aug 17	$0.03	0.00	0.0%	$0.03	$0.03	$0.03	229,894
Fri, Aug 14	$0.03	+0.005	+20.0%	$0.03	$0.03	$0.025	209,940
Thu, Aug 13	$0.025	-0.005	-16.7%	$0.03	$0.035	$0.025	216,599
Wed, Aug 12	$0.03	+0.005	+20.0%	$0.03	$0.035	$0.03	382,570
Tue, Aug 11	$0.025	0.00	0.0%	$0.025	$0.03	$0.025	18,298
Mon, Aug 10	$0.025	-0.005	-16.7%	$0.025	$0.03	$0.025	223,403
Fri, Aug 7	$0.03	0.00	0.0%	$0.03	$0.03	$0.03	12,500
Thu, Aug 6	$0.03	+0.005	+20.0%	$0.035	$0.035	$0.025	97,900
Wed, Aug 5	$0.025	0.00	0.0%	$0.04	$0.04	$0.025	78,159
Tue, Aug 4	$0.025	—	—	$0.03	$0.032	$0.025	30,000

Ticker: Frankfurt:4YX
Asset type: Stock
Sector: Health care
Industry: Biotechnology
Exchange: Frankfurt
Currency: EUR

What changed lately

Latest news release · Nov 2, 2026
Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

Latest news

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

Nov 2, 2026

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder

Oct 28, 2026

Closed $0.025 (0.0%) on Oct 28, 2026

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression

Oct 16, 2026

Closed $0.025 (0.0%) on Oct 16, 2026

Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor

Oct 14, 2026

Closed $0.025 (0.0%) on Oct 14, 2026

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV

Oct 8, 2026

Closed $0.025 (0.0%) on Oct 8, 2026

Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences

Jul 29, 2026

Red Light Holland Announces New Filament Health PEX010 European Research Shipment

Jul 16, 2026

Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg

Jul 8, 2026

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre

Jul 7, 2026

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health

Jun 18, 2026

All Rhelion Life Sciences Corp. news

Decks

Red Light Holland — Investor Presentation (December 2024)
Investor deck · 30 slides · December 2024
Red Light Holland — Investor Presentation (September 2022)
Investor deck · 24 slides · September 2022

Rhelion Life Sciences Corp. on 6ix

Sector: Health care
Industry: Biotechnology
News releases: 46 in the last 12 months · 128 in all · newest Nov 2, 2026 · oldest 2012
Decks: 2 decks · latest December 2024

Where Rhelion Life Sciences Corp. is listed

Listing	Exchange	Country	Currency
CSE:RHEL · Home listing	CSE	Canada	CAD
OTC:TRUFF	OTC	United States	USD
Cboe Canada:TRIP	Cboe Canada	Canada	CAD
Frankfurt:4YX · This page	Frankfurt	Germany	EUR
LS Exchange:A2P5KA	LS Exchange	Germany	EUR
gettex:4YX	gettex	Germany	EUR
Lang & Schwarz:A2P5KA	Lang & Schwarz	Germany	EUR
Stuttgart:4YX	Stuttgart	Germany	EUR
Munich:4YX	Munich	Germany	EUR

Frankfurt:4YX Rhelion Life Sciences Corp. Aktie

Prices by listing

Daily closes

What changed lately

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

Latest news

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Agreement to Supply PEX010 to Linkoping University for PsiloSAD Trial in Social Anxiety Disorder

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health to Supply Belgium's First Psilocybin Compassionate Use Program, to Help Open the Door to Patient Access for Treatment-Resistant Depression

Rhelion Life Sciences Reappoints Dr. Robin Carhart-Harris as Scientific Advisor

Rhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Licence Agreement with the University of California, San Francisco for a Phase 2 Trial of Psilocybin in Methamphetamine Use Disorder Among People with HIV

Red Light Holland Reports Fiscal 2026 Audited Year-End Results and Provides Update on Rhelion Life Sciences

Red Light Holland Announces New Filament Health PEX010 European Research Shipment

Red Light Holland Announces Filament Health's Largest-Ever Manufacturing Run of PEX010, the Standardized and Patented Natural Psilocybin Drug Candidate Trusted Across 80+ Studies Globally, Now Offering the Widest Standardized Dosing Range, from 0.5 mg to 25 mg

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre

Red Light Holland Reports Positive Preclinical Study Results for Coca in Weight Gain Prevention Post GLP-1 from Magdalena Biosciences, the Joint Venture Held Through Its Wholly Owned Subsidiary, Filament Health

Decks

Red Light Holland — Investor Presentation (December 2024)

Red Light Holland — Investor Presentation (September 2022)

Rhelion Life Sciences Corp. on 6ix

Where Rhelion Life Sciences Corp. is listed